N. Zanaletti

TL;DR: In this paper, a single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020, and the primary end point was OS. Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety.

TL;DR: Testing RAS/BRAF mutations on plasma using the Idylla™ Biocartis platform is feasible and reliable in mCRC patients in clinical practice and correlated the results of liquid biopsy and standard tissue-based next generation sequencing analyses to patient clinical features.

TL;DR: A case of a patient diagnosed with metastatic colorectal cancer who experienced an atypical haemolytic-uraemic syndrome (aHUS) during chemotherapy treatment with FOLFOX6 scheme is reported, emphasising the importance of considering TMA as a possible diagnosis in patients with cancer presenting with haenolytic non-immune mediate anaemia and thrombocytopaenia associated with worsening of renal function.

TL;DR: An interesting correlation between IFN-γ/IL-10 ratio and response to anti-PD-1 therapy in advanced melanoma patients is suggested, suggesting a new biomarker that could be easily incorporated in clinical practice.

TL;DR: Comprehensive genomic profiling (CGP) could be proposed in clinical practice in order to select patients that could most benefit from the analysis proposed, like patients with good performance status without any available treatments or with unexpected resistance to a therapy.